Novo Nordisk Outbids Pfizer for Obesity Biotech Metsera in $9 Billion Deal

Bidding War for Obesity Biotech

• 🎯 Novo Nordisk has launched a surprise bid for US biotech firm Metsera, topping Pfizer's offer in a move to gain an advantage in the lucrative weight-loss drug market.
• 📈 The news sent Metsera's shares soaring over 23% on Thursday, building on previous gains.

Financials and Offers

• 💰 Novo Nordisk is offering up to $8.5 billion for Metsera, valuing the company at $9 billion, which surpasses Pfizer's $7.3 billion bid.
• ⏳ Metsera has deemed Novo's offer superior and has given Pfizer four days to respond.

Competitive Landscape and Drug Development

• 🚀 Both Novo Nordisk and Pfizer are vying for access to Metsera's experimental drug pipeline, including a once-a-month injectable weight-loss candidate.
• ⚠️ Pfizer has called Novo's revised offer "reckless" and stated it would pursue all legal avenues to defend its rights, citing concerns about competition.
• ⚡ Novo Nordisk's move comes after internal pressure to accelerate its efforts in the obesity market, where it faces competition from Eli Lilly.

Rival Company Performance

• 📊 Eli Lilly, a key competitor, recently raised its full-year profit and revenue forecasts.
• 💊 Lilly is also advancing its own weight-loss drug pipeline, with an experimental pill set for submission to the FDA this quarter.